Scaling Proteomics: Balancing Performance and Measuring Enough Proteins
Explore the advancements in proteomics platforms, with a focus on precision, sensitivity and specificity
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains?
To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
Additionally, since most proteins not yet measurable are low-abundance non-secreted proteins, the webinar will address whether credible physiological signals exist in that fraction and if expanding proteomic measurements to encompass the entire proteome is worthwhile.
Stephen Williams, MD, PhD
Chief Medical Officer
Standard BioTools
Stephen Williams, MD, PhD, is the Chief Medical Officer at Standard BioTools and oversees clinical application of the SomaScan® Platform.
Before joining Standard BioTools, Dr. Williams co-founded the pharma consultancy Decisionability, LLC and authored the book Decisionability: The skill to make your decisions productive, practical and painless. Previously, he worked at Pfizer, Inc., initially in experimental medicine and later as the Vice President and Worldwide Head of Clinical Technology. He was also on the National Advisory Council for Biomedical Imaging and Bioengineering at the U.S. National Institutes of Health. He helped launch the Alzheimer’s Disease Neuroimaging (ADNI) study and form the FDA-FNIH-PhRMA biomarker consortium. He led or co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Dr. Williams has degrees in physiology, medicine and surgery, and received his doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College, London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.
Scaling proteomics: Balancing performance and measuring enough proteins
A presentation by Stephen Williams, MD, PhD
More webinars
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.